Sumitomo Pharma Beheer

Beheer criteriumcontroles 2/4

De CEO Sumitomo Pharma is Toru Kimura, benoemd in Jan2016, heeft een ambtstermijn van 8.83 jaar. bezit rechtstreeks 0.02% van de aandelen van het bedrijf, ter waarde € 296.95K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.2 jaar en 3.9 jaar.

Belangrijke informatie

Toru Kimura

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	8.8yrs
Eigendom CEO	0.02%
Management gemiddelde ambtstermijn	2.2yrs
Gemiddelde ambtstermijn bestuur	3.9yrs

Recente managementupdates

Recent updates

CEO

Toru Kimura (64 yo)

8.8yrs

Tenure

Mr. Toru Kimura, Ph D., is Representative Director, President & CEO of Sumitomo Pharma Co. Ltd. from June 25, 2024.Mr. Toru serves as Director at Sumitomo Pharma America, Inc. since 2024. He served as Rep...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Toru Kimura	Representative Director	8.8yrs	geen gegevens	0.020% € 296.9k
Motoyuki Sakai	Representative Director and Executive VP of Corporate Planning	less than a year	geen gegevens	geen gegevens
Hiroyuki Baba	Mngg Exec. Officer of Global Data Design	7.6yrs	geen gegevens	0.0015% € 22.8k
Naoki Noguchi	Executive Officer of Corporate Governance & Communications	2.6yrs	geen gegevens	geen gegevens
Yoshiharu Ikeda	Managing Executive Officer of Drug Research Division	4.4yrs	geen gegevens	0.0038% € 57.2k
Koichi Kozuki	E.O. of R. Aff.	1.8yrs	geen gegevens	geen gegevens
Shigeyuki Nishinaka	Managing Executive Office	7.6yrs	geen gegevens	0.0020% € 30.4k
Isao Shimizu	Executive Officer	1.8yrs	geen gegevens	geen gegevens
Kenji Ueno	Executive Officer	1.8yrs	geen gegevens	geen gegevens
Hideyuki Harada	Managing Exe. Officer of Tech. R&D Div.	3.6yrs	geen gegevens	geen gegevens
Tsutomu Nakagawa	Executive Officer	1.8yrs	geen gegevens	0.00076% € 11.5k
Yumi Sato	Exe Off of Drug Dev Div	1.8yrs	geen gegevens	geen gegevens

2.2yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van DPM wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Toru Kimura	Representative Director	8.4yrs	geen gegevens	0.020% € 296.9k
Motoyuki Sakai	Representative Director and Executive VP of Corporate Planning	less than a year	geen gegevens	geen gegevens
Yoshiharu Ikeda	Managing Executive Officer of Drug Research Division	4.4yrs	geen gegevens	0.0038% € 57.2k
Tsutomu Nakagawa	Executive Officer	less than a year	geen gegevens	0.00076% € 11.5k
Saeko Arai	Independent Outside Director	6.4yrs	geen gegevens	geen gegevens
Minoru Usui	Independent Outside Director	3.4yrs	geen gegevens	geen gegevens
Nobuhiro Endo	Independent Outside Director	5.4yrs	geen gegevens	geen gegevens
Hiroshi Niinuma	Director	less than a year	geen gegevens	geen gegevens
Takashi Kutsunai	Full-Time Audit & Supervisory Board Member	6.4yrs	geen gegevens	0.0065% € 98.9k
Yoshio Iteya	Outside Audit & Supervisory Board Member	6.4yrs	geen gegevens	geen gegevens
Hisayoshi Kashima	Full-Time Audit & Supervisory Board Member	1.4yrs	geen gegevens	0.0035% € 53.2k
Koji Fujimoto	Independent Outside Director	2.4yrs	geen gegevens	geen gegevens

3.9yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van DPM wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).

Sumitomo Pharma Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Less than half of directors are independent

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 25, 2024

Sumitomo Pharma Co., Ltd. Announces Executive Changes

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 27, 2023

Less than half of directors are independent

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 23, 2022

Recent updates

Sumitomo Pharma Co., Ltd. to Report Q3, 2025 Results on Jan 31, 2025

Second quarter 2025 earnings released: JP¥121 loss per share (vs JP¥72.68 loss in 2Q 2024)

Sumitomo Pharma Co., Ltd.(TSE:4506) dropped from FTSE All-World Index (USD)

Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG for the Treatment of Type 2 Diabetes in Japan

Less than half of directors are independent

New major risk - Share price stability

Sumitomo Pharma Co., Ltd. to Report Q2, 2025 Results on Oct 30, 2024

First quarter 2025 earnings released: EPS: JP¥40.11 (vs JP¥97.83 loss in 1Q 2024)

New minor risk - Share price stability

Sumitomo Pharma Co., Ltd. to Report Q1, 2025 Results on Jul 31, 2024

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 25, 2024

Full year 2024 earnings released: JP¥793 loss per share (vs JP¥188 loss in FY 2023)

Sumitomo Pharma Co., Ltd. to Report Fiscal Year 2024 Results on May 14, 2024

Third quarter 2024 earnings released: JP¥126 loss per share (vs JP¥28.24 loss in 3Q 2023)

Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

Sumitomo Pharma Co., Ltd. to Report Q3, 2024 Results on Jan 31, 2024

European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of Endometriosis

Gedeon Richter Plc., Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH Receives European Commission grant for Commercialisation of RYEQO®

Second quarter 2024 earnings released: JP¥72.68 loss per share (vs JP¥96.63 loss in 2Q 2023)

Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending March 31, 2024

New major risk - Share price stability

Sumitomo Pharma Announces Positive Topline Results from Phase 3 Clinical Studies Evaluating Vibegron in Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia

Now 22% undervalued after recent price drop

Sumitomo Pharma Co., Ltd. to Report Q2, 2024 Results on Oct 31, 2023

New minor risk - Share price stability

Sumitomo Pharma Co., Ltd. (TSE:4506) acquired Assets and rights related lefamulin in China, Hong Kong, Macau and Taiwan from Nabriva Therapeutics plc (OTCPK:NBRV.F), Nabriva Therapeutics US, Inc, Nabriva Therapeutics GmbH and Nabriva Therapeutics Ireland Dac for $15 million.

Now 28% undervalued after recent price drop

First quarter 2024 earnings released: JP¥97.83 loss per share (vs JP¥78.30 profit in 1Q 2023)

Sumitomo Pharma and Otsuka Announce Topline Results from Phase 3 Diamond 1 and Diamond 2 Clinical Studies Evaluating Ulotaront in Schizophrenia

Sumitomo Pharma Co., Ltd. Announces Executive Changes

Sumitomo Pharma Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023

Revolka Ltd. Announces Milestone Achievement in the Collaborative Research with Sumitomo Pharma Co., Ltd

HEALIOS K.K. and Sumitomo Pharma Co. Ltd. Announces Start of Phase 1/2 Study in RPE Tear Using RPE Cells Derived from Allogeneic iPS Cells (HLCR011)

Sumitomo Pharma Oncology, Inc. Presents Updated Preliminary Data from Phase 1/2 Clinical Study Evaluating Investigational Agent TP-3654 in Patients with Myelofibrosis at European Hematology Association 2023 Hybrid Congress

Full year 2023 earnings released: JP¥188 loss per share (vs JP¥142 profit in FY 2022)

Sumitomo Pharma Co., Ltd. Announces Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 27, 2023

Upcoming dividend of JP¥7.00 per share at 3.5% yield

Sumitomo Pharma Co., Ltd. to Report Fiscal Year 2023 Results on May 15, 2023

Third quarter 2023 earnings released: JP¥28.24 loss per share (vs JP¥24.94 profit in 3Q 2022)

Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Mitsui & Co., Ltd. (TSE:8031) agreed to acquire Sumitomo Pharma Animal Health Co., Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506).

Sumitomo Pharma Co., Ltd. to Report Q3, 2023 Results on Jan 31, 2023

MediPal Holdings Corporation (TSE:7459) entered into a Share Purchase agreement to acquire Sumitomo Pharma FOOD & CHEMICAL Co., LTD. from Sumitomo Pharma Co., Ltd. (TSE:4506).

Less than half of directors are independent

Second quarter 2023 earnings released: JP¥96.63 loss per share (vs JP¥79.66 profit in 2Q 2022)

Sumitomo Pharma Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Sumitomo Pharma Co., Ltd. Provides Impairment Loss Guidance for the Second Quarter of the Fiscal Year Ending March 31, 2023

Upcoming dividend of JP¥14.00 per share

Now 20% undervalued

Sumitomo Pharma Co., Ltd. to Report Q2, 2023 Results on Oct 31, 2022

First quarter 2023 earnings released: EPS: JP¥78.30 (vs JP¥12.09 in 1Q 2022)

Sumitomo Pharma Co., Ltd. Provides Earnings Guidance for the Year Ending March 31, 2023

Sumitomo Pharma Co., Ltd. to Report Q1, 2023 Results on Jul 29, 2022

Full year 2022 earnings released: EPS: JP¥142 (vs JP¥142 in FY 2021)

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 23, 2022

Less than half of directors are independent

Less than half of directors are independent

Upcoming dividend of JP¥14.00 per share

Sumitomo Dainippon Pharma Announces Personnel Changes Including Representative Director and Organizational Realignment

Sumitomo Dainippon Pharma Co., Ltd. to Report Fiscal Year 2022 Results on May 13, 2022

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Sumitomo Dainippon Pharma Co., Ltd. Provides Financial Guidance for the Year Ending March 31, 2022

Now 22% undervalued after recent price drop

Sumitomo Dainippon Pharma Announces Phase 3 Study of Investigational Cancer Vaccine DSP-7888

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS JP¥79.66 (vs JP¥47.92 in 2Q 2021)

Upcoming dividend of JP¥14.00 per share

Poxel and Sumitomo Dainippon Pharma Announce Product Launch in Japan for TWYMEEG® as Treatment for Type 2 Diabetes